Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively

Journal of Nuclear Cardiology

Volumn 20, Issue 3, 2013, Pages 443-464

  Schwartz, Ronald G ^a   Jain, Diwakar ^b   Storozynsky, Eugene ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

cardiomyopathy; echocardiography; heart failure; magnetic resonance imaging; Radionuclide angiography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IMCIROMAB PENTETATE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 2; METHOTREXATE; MITOMYCIN; PACLITAXEL; PENTOSTATIN; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

APOPTOSIS; BLOOD PRESSURE MONITORING; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY SPASM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; FOLLOW UP; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; GENETIC MARKER; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HYPERTENSION; INCIDENCE; INTERMETHOD COMPARISON; ISCHEMIA; LOW DRUG DOSE; LUNG CANCER; NON INVASIVE MEASUREMENT; NONHUMAN; OVARY CANCER; PERICARDITIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SIDE EFFECT; SYSTOLIC DYSFUNCTION; THORAX PAIN; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VEIN THROMBOSIS;

ALGORITHMS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY, THREE-DIMENSIONAL; HEART; HEART FAILURE; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; RADIONUCLIDE IMAGING; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84878013653     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-013-9707-1     Document Type: Review

References (101)

1. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-47.
2. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008.
3. Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J 2011;38:263-5.
4. Maitland ML, Bakris GL, Black HR, Chen HX, Durand J-B, Elliott WJ, et al. Cardiovascular Toxicities Panel, convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604.
5. Lefrak EA, Pit'ha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973;32:302-14.
6. Alexander J, Dainiak N, Berger H, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-83.
7. Choi BW, Hi B, Schwartz PE, Alexander I, Wackers FJTh, Gottschalk A, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638-43.
8. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: A seven year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-18.
9. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132-9.
10. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992;89:942-9.
11. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
12. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.
13. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-36.
14. Cameron EH, Lipshultz SE, Tarbell NJ, et al. Cardiovascular disease in long term survivors of pediatric Hodgkin's disease. Prog Pediatr Cardiol 1998;8:139-44.
15. Plana JC. Chemotherapy and the heart. Rev Esp Cardiol 2011;64:409-15.
16. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-72.
17. Von Hoff DD, Layard M. Risk factors for development of daunorubicin cardiotoxicity. Cancer Treat Rep 1981;65(Suppl 4):19-23.
18. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.
19. Panjrath GS, Jain D. Trastuzumab-induced cardiac dysfunction. Nucl Med Commun 2007;28:69-73.
20. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982;50:32-41.
21. Lindenfeld J, et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Cardiac Fail 2010;16:2010.
22. Panjrath GS, Patel V, Valdiviezo CI, Narula N, Narula J, Jain D. Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol 2007;49:2457-64.
23. Mackey JR, Clemons M, Cote MA, et al. Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008;15:24-35.
24. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994;28:374.
25. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: A prospective study. Oncology 1993;50:441.
26. Palmeri ST, Bonow RO, Myers CE, Seipp C, Jenkins J, Green MV, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607-13.
27. Van Kriekinge SD, Berman DS, Germano G. Automatic quantification of left ventricular ejection fraction from gated blood pool SPECT. J Nucl Cardiol 1999;6:498-506.
28. Wexler O, Yoder SR, Elder JL, Mackin ML, Chen L, Mixon L, et al. Effect of gender on cardiovascular risk stratification with ECG gated SPECT left ventricular volume indices and ejection fraction. J Nucl Cardiol 2009;16:28-37.
29. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
30. Daou D, Harel F, Helal BO, et al. Electrocardiographically gated blood-pool SPECT and left ventricular function: Comparative value of 3 methods for ejection fraction and volume estimation. J Nucl Med 2001;42:1043-9.
31. Hambye AS, Vervaet A, Dobbeleir A. Variability of left ventricular ejection fraction and volumes with quantitative gated SPECT: Influence of algorithm, pixel size and reconstruction parameters in small and normal-sized hearts. Eur J Nucl Med Mol Imaging 2004;31:1606-13.
32. Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging 2008;35:851-85.
33. Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine Endorsed by the American College of Emergency Physicians. J Am Coll Cardiol 2009;53:2201-29.
34. Cottin Y, Touzery C, Dalloz F, et al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: Evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998;21:665-70.
35. Groch MW, DePuey EG, Belzberg AC, Erwin WD, Kamran M, Barnett CA, et al. Planar imaging versus gated blood-pool SPECT for the assessment of ventricular performance: A multicenter study. J Nucl Med 2001;42:1773-9.
36. McManus DD, Shah SJ, Fabi MR, Rosen A, Whooley MA, Schiller NB. Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: Data from the heart and soul study. J Am Soc Echocardiogr 2009;22:190-7. doi: 10.1016/j.echo.2008.11.005.
37. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr 2008;21:1179-201.
38. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77-84.
39. Mor-Avi V, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol 2013;61:85-7.
40. Marchandise B, et al. Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-8.
41. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62-9.
42. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7:141-6.
43. Banchs J, Jefferies JL, Plana JC, Hundley WG. Imaging for cardiotoxicity in cancer patients. Tex Heart Inst J 2011;38:268-9.
44. Civelli M, Cardinale D, Martinoni A, Lamantia G, Colombo N, Colombo A, et al. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 2006;111:120-6.
45. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Nes KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012. doi: 10.1200/JCO.2011.40.3584.
46. de Geus-Oei LF, Mavinkurve-Groothuis AMC, Bellersen L, Gotthardt M, Oyen WJG, Kapusta L, et al. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med 2011;52:560-71.
47. Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001;42:1062-76.
48. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
49. 123Imetaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008;29:1147-59.
50. Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol Rep 2006;8:131-8.
51. Wakasugi S, Fischman AJ, Babich JW, et al. Metaiodobenzylguanidine: Evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 1993;34:1282-6.
52. Valdes Olmos RA, ten Bokkel Huinink ww, ten Hoeve RF, van Tinteren H, Bruning PF, can Vlies B, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer 1995;31A:26-31.
53. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. J Am Coll Cardiol 2010;55:2212-21.
54. 123I-MIBG studies in the early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.
55. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 2004;11:603-16.
56. Carrio I, Lopez-Pousa A, Estorch M, et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 1993;34:1503-7.
57. Kremer LCM, Tiel-van Buul MMC, Ubbink MC, Offringa M, Ottenkamp J, Olmos RV, et al. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children. J Clin Oncol 1999;17:1208-11.
58. Bennink RJ, van den Hoff MJ, can Hemert FJ, de Bruin KM, Spijkereboer AL, van den Vanderheyden J, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 2004;45:842-8.
59. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin induced apoptosis: Implications in cardiotoxicity. Mol Cell Biochem 2002;234-235:119-24.
60. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy: From the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-52.
61. Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: Comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med 2003;17:481-8.
62. 111Indium- trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007;43:2046-51.
63. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121-9.
64. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62.
65. Roziakova L, Bojtarova E, Mistrik M, Dubrava J, Gergel J, Lenkova N, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res 2012;9:13. doi: 10.1186/1756-9966-31-13.
66. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant traztuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.
67. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2007;97:318-26.
68. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity systematic review of the literature and recommendations for use. Am J Clin Pathol 2008;130:688-95.
69. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30:1422-8.
70. Lenihan DJ, Fisch M. Effectiveness of using biomarkers to detect and identify cardiotoxicity and describe treatment (PREDICT). http://clinicaltrials. gov/ct2/show/NCT01311843. Accessed 30 Mar 2013.
71. Jurcut R, Wildiers H, Ganame J, D'hooge J, De Backer J, Denys H, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 2008;21:1283-9.
72. Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: A speckle tracking echocardiographic study. Heart 2010;96:701-7.
73. Sawaya H, Sebaq IA, Plana JC, Januzi JL, Ky B, Gosavi S, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-80.
74. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.
75. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol 2012;19:377-88.
76. Lipschultz SE, Cochran TR, Wilkinson JD. Screening for long-term cardiac status during cancer treatment. Circ Cardiovasc Imaging 2012;5:555-8.
77. Tantawy AA, Elmasry OA, Shaaban M, Toaima DN, El Shahat AM. Radionuclide ventriculography detects early anthracycline cardiotoxicity in children with Hodgkin lymphoma. J Pediatr Hematol Oncol 2011;33:e132-7.
78. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003;21:2349-56.
79. Pratt CB, Ransom JL, Evans WE. Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep 1978;62:1381-5.
80. Mulrooney DA, Yeazel MW, Kawashina T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
81. Beeres SLMA, Bengel FM, Bartunek J, Atsma DE, Hill JM, Vanderheyden M, et al. Role of imaging in cardiac stem cell therapy. J Am Coll Cardiol 2007;49:1137-48.
82. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR. Appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol 2006;48:1475-97.
83. Zagrosek A, Abdel-Aty H, Boye P, Wassmuth R, Messroghli D, Utz W, et al. Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. J Am Coll Cardiol Imaging 2009;2:131-8.
84. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in traztuzumab induced cardiomyopathy. J Cardiovasc Mag Res 2008;10:5.
85. Wassmuth R, Lentszch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study. Am Heart J 2001;141:1007-13.
86. Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, et al. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging 2010;3:550-8.
87. Westwood M, Anderson LJ, Firmin DN, et al. A single breathhold multiecho T2*cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003;18:33-9.
88. Dash R, Chung J, Chan T, Yamada M, Barral J, Nishimura D, et al. A molecular MRI probe to detect treatment of cardiac apoptosis in vivo. Magn Reson Med 2011;66:1152-62.
89. Steel K, Broderick R, Gandla V, Larose E, Resnic F, Jerosch-Herold M, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation 2009;120:1390-400.
90. Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS, Sampaio RO, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 2010;56:278-87.
91. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87.
92. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-74.
93. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
94. Mekinian A, Lions C, Leleu X, Duhamel A, Lamblin N, Coiteux V, et al. Prognosis assessment of cardiac involvement of systemic AL amyloidosis by magnetic resonance imaging. Am J Med 2010;123:864-8.
95. Thorburn A, Frankel AE. Apoptosis and anthracycline cardiotoxicity. Mol Cancer Ther 2006;5:197-9.
96. Horie T, Ono K, Nishi H, Nagao K, Minako K, Watanable S, et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010;87:656-64.
97. Shi J, Zhang L, Zhang Y, Surma M, Payner RM, Wei L. Down-regulation of doxorubicin-induced myocardial apoptosis accompanies postnatal heart maturation. Am J Physiol Heart Circ Physiol 2012. doi: 10.1152/ajpheart.00844.2011.
98. 2+-ATPase gene transcription. Circ Res 2000;86:8-14.
99. Sadeghi M, Schwartz RG, Beanlands RS, Al-Mallah MH, Bengel FM, Borges-Neto S, et al. for the Cardiovascular Council Board of Directors of the Society of Nuclear Medicine. Cardiovascular nuclear imaging: Balancing proven clinical value and potential radiation risk. J Nucl Med 2011;52:1163-4.
100. Lal H, Kolaja KL, Force T. Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol 2013;61:267-74.
101. Panjrath GS, Jain D. Imaging cancer chemotherapy-induced cardiotoxicity. J Nucl Cardiol 2006;13:415-26.